MedPath

HighCycle: Effect of Acetazolamide on Pulmonary Artery Pressure in Women Compared to Men

Phase 4
Recruiting
Conditions
High Altitude
Interventions
Drug: Placebo
Registration Number
NCT06498505
Lead Sponsor
University of Zurich
Brief Summary

Randomized clinical trial evaluating the effect of acetazolamide on pulmonary artery pressure in women compared to men travelling to 3600 m.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
270
Inclusion Criteria
  • Healthy, non-smoking men and women, age 18-44 years, without any diseases and need of regular medication (including oral contraceptives).
  • BMI >18 kg/m2 and <30 kg/m2
  • Born, raised and currently living at altitudes <1000 m
  • Written informed consent
  • Premenopausal women with an eumenorrheic cycle
Exclusion Criteria
  • Other types of contraceptvies (hormonal intrauterine device, vaginal ring, subcutaneous injections or implants, among others)
  • Pregnancy or nursing
  • Anaemic (haemoglobin concentration <10g/dl)
  • Any altitude trip <4 weks before the study
  • Allergy to acetazolamide and other sulfonamides

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
WOMEN - PLACEBO oral capsulePlaceboPlacebo (capsules identically looking as acetazolamide capsules; 1 in the morning, 1 in the evening), orally. Medication starts 24 hours before ascent to 3600 m until the morning after the second night at 3600 m.
MEN - PLACEBO oral capsulePlaceboPlacebo (capsules identically looking as acetazolamide capsules; 1 in the morning, 1 in the evening), orally. Medication starts 24 hours before ascent to 3600 m until the morning after the second night at 3600 m.
MEN - ACETAZOLAMIDE oral capsuleAcetazolamideAcetazolamide 250 mg/day (capsules @125 mg; 1 in the morning, 1 in the evening), orally. Medication starts 24 hours before ascent to 3600 m until the morning after the second night at 3600 m
WOMEN - ACETAZOLAMIDE oral capsuleAcetazolamideAcetazolamide 250 mg/day (capsules @125 mg; 1 in the morning, 1 in the evening), orally. Medication starts 24 hours before ascent to 3600 m until the morning after the second night at 3600 m
Primary Outcome Measures
NameTimeMethod
Pulmonary artery Pressure (PAP)Day 2 at 760 m and Day 2 at 3600 m

Sex-related difference in the altitude-induced change in RV/RA in mmHg assessed by echocardiography between acetazolamide and placebo group.

Secondary Outcome Measures
NameTimeMethod
Lung cometsDay 2 at 760 m and Day 2 at 3600 m

Sex-related difference in the altitude-induced change in ultrasound lung comets assessed by echocardiography between acetazolamide and placebo group.

Parameters of right heart functionDay 2 at 760 m and Day 2 at 3600 m

Sex-related difference in the altitude-induced change in parameters of right heart function assessed by echocardiography between acetazolamide and placebo group.

Trial Locations

Locations (1)

National Center for Cardiology and Internal Medicine

🇰🇬

Bishkek, Kyrgyzstan

© Copyright 2025. All Rights Reserved by MedPath